Alucent Biomedical Inc.

Alucent Biomedical Inc. focuses on developing innovative digital health solutions that enhance patient engagement and operational efficiency within the healthcare sector. Founded in 2017, Alucent Biomedical Inc. is headquartered in Salt Lake City, US, specializing in digital health solutions.

The company raised USD 35 mn in Series B funding on October 1, 2020, co-led by Fresenius Medical Care Ventures. Myles Greenberg serves as the CEO. Alucent Biomedical Inc. provides advanced digital health solutions that improve user engagement and operational efficiency in healthcare.

Their offerings include patient engagement platforms and data management tools tailored for healthcare providers, focusing on improving care delivery and patient outcomes. The company's revenue is generated through a subscription-based model, allowing healthcare organizations to access their suite of services. Clients subscribe to monthly or annual plans, with options for additional features such as analytics and data integration. The services cater primarily to healthcare providers, enhancing their patient engagement and operational capabilities.

Alucent Biomedical Inc. aims to release new healthcare data analytics products by the end of 2023, targeting expansion into European and Asian markets by 2025. The recent Series B funding of USD 35 mn will be used to support product development and market entry initiatives.